Floatz logo

Onivyde

Recurrent Peripheral Primitive Neuroectodermal Tumor

St. Jude Children's Research HospitalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Recurrent Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2B
Tazemetostat
National Cancer Institute (NCI)
Phase 2B
PI3K/MTOR INHIBITOR LY3023414
National Cancer Institute (NCI)
Phase 2B
VEMURAFENIB
National Cancer Institute (NCI)
Phase 2CCC
Ensartinib
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

Onivyde is also rated in:

Metastatic Pancreatic CancerDormant
B
Indicative ·
60 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
Ewing sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →